|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to the C-terminal residues S(129) E E G Y Q D Y E P E A(140) of human alpha synuclein protein.|
|Storage buffer||whole serum|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||1:500 - 1:3000|
|Western Blot (WB)||1:500 - 1:3000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA1-18264 detects alpha Synuclein from human, mouse, and rat samples.
PA1-18264 has been successfully used in immunohistochemistry and Western blot procedures.
The PA1-18264 immunogen is a synthetic peptide corresponding to the C-terminal residues S(129) E E G Y Q D Y E P E A(140) of human alpha synuclein protein, conjugated to Blue Carrier Protein. The sequence is conserved in monkey and pig.
After reconstitution, store aliquots at -20 C or 4 C with appropriate antibacterial agent. Avoid freeze/thaw cycles.
Reconstitute with 100 ul of distilled water. Glycerol (1:1) may be added for additional stability.
Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease.
PA1-18264 was used in western blot to assess the efficiency and potential safety of miRNA replacement therapy for Alzheimer's disease
|Parsi S,Smith PY,Goupil C,Dorval V,Hébert SS||Molecular therapy. Nucleic acids (4:null)||2015|
Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease.
PA1-18264 was used in immunohistochemistry to study the alpha-synuclein-presenilin-1 interaction and its potential role in the overlapping neuropathologies observed in dementia with Lewy bodies and familial Alzheimer's disease
|Winslow AR,Moussaud S,Zhu L,Post KL,Post KL,Dickson DW,Berezovska O,McLean PJ||Brain : a journal of neurology (137:1958)||2014|